114 Views
Tuesday Poster Session
Category: IBD
Andrew Leopold, MD
University of Maryland School of Medicine
Baltimore, MD, United States
Age >60 (n=15) | Age < 60 (n=73) | χ2 and p value | Frail (n=17) | Non-frail (n=71) | χ2 and p value | |
Immunomodulator (n=33) | 5 (33%) | 28 (38%) | χ2=0.13, p=0.73 | 7 (41%) | 26 (36%) | χ2=0.12, p=0.73 |
Anti-TNF (n=66) | 7 (47%) | 59 (80%) | χ2=7.75, p=0.005 | 10 (56%) | 56 (79%) | χ2=2.94, p=0.086 |
Other biologic agents (n=38) | 10 (68%) | 28 (38%) | χ2=4.1, p=0.043 | 8 (47%) | 30 (42%) | χ2=0.18, p=0.67 |
Total medication changes | 1.6±0.99 | 1.2±1.0 | p=0.17 | 1.9±1.1 | 1.1±0.94 | p=0.0051 |
Total steroid tapers | 0.93±0.80 | 0.89±0.86 | p=0.85 | 1.1±0.83 | 0.86±0.85 | p=0.38 |
Average number of infections | 0.86±1.1 | 0.99±1.2 | p=0.73 | 2.0±1.5 | 0.72±0.97 | p< 0.0001 |
IBD related hospitalizations | 0.33±0.82 | 0.96±1.8 | p=0.19 | 1.5±1.8 | 0.70±1.6 | p=0.086 |
IBD related surgeries | 0.27±0.59 | 0.29±0.63 | p=0.91 | 0.59±1.0 | 0.21±0.48 | p=0.024 |